31 / 231
Brasil
PackTrends
2020
31
packaging market: world and Brazil
Table 1.50
Historical trends and projections for beverage packaging consumption: Volume
(tonnes)
Material
Thousand
tonnes
2007
Thousand
tonnes
2011
Average growth
2007-2011
Thousand
tonnes
2015*
Average growth
2011-2015*
Glass
733.9
910.1
5.5%
1,035.5
3.3%
Plastics
630.3
884.9
8.9%
1,102.9
5.7%
Corrugated board
486.4
640.1
7.1%
779.5
5.0%
Metals
319.1
428.9
7.7%
531.8
5.5%
Paper
269.7
333.4
5.4%
414.1
5.6%
Flexibles
62.2
73.3
4.2%
89.6
5.1%
TOTAL
2,501.5
3,270.6
6.9%
3,953.4
4.9%
*Estimate
Source: DATAMARK
In the last ten years, the pharmaceutical sales,
including generics, OTC (over-the-counter) and other
pharmaceuticals under medical prescription, have
increased 43.5%, reaching 2.34 billion of unities
at the end of 2011. The fast growth of basically all
types of pharmaceuticals has stimulated the major
pharmaceutical companies to invest in expanding of
industrial facilities, clinical studies and acquisitions.
About R$ 5 billion in investments, business and
acquisitions shook the Brazilian pharmaceutical market
in 2011.
Major investments are also a way for the
pharmaceutical companies to prepare to face a new
era without the blockbuster patented products. The
expiration of a patent generates, for the manufacturers
and P&D holders, a loss of US$ 500 million in sales in
Brazil, and in 2011, around 25 pharmaceuticals had
their patents expire. In order to face this transformation,
one of the main strategic initiatives by the sector giants is
product innovation and investment in research to speed
up the development of new therapeutic treatments.
The considerable increase in the investments in
research, caused by the patent expiration, compares
with the growth of generic pharmaceuticals share in the
Brazilian market, which closed 2011 with 20.5% of
pharmaceutical sector sales.
The packaging sector for pharmaceuticals, that
ranges from laminated blisters and paperboard cartons
to glass bottles, have gotten benefits from the soaring
of the demand for generic pharmaceuticals, generating
approximately R$ 606 million in 2011, an increase of
25% versus 2010, passing the 13% growth rate of the
pharmaceutical sector. Table 1.5 shows the relationship
of the ten largest companies of the sector in 2010 (by
sales) (PORTAL FARMACÊUTICO, 2012; FÓRUM DE
LÍDERES, s.d.).
The OTC pharmaceuticals market is increasing,
having been pushed mainly by the expansion of
governmental healthcare programs, as well as the
increase of the discretionary income of the Brazilian
consumer.
The growth of the C class’s purchasing power and
the decrease in price of pharmaceuticals, thanks to
the advent of the generics, has made pharmaceuticals
more accessible to most of the Brazil’s population. The
average spend per capita in 2012 was R$ 386.43,
versus R$ 337 from 2011. Classes B and C will be
mainly responsible for that consumption. Together, they
correspond to 80% of the total, with spending of R$ 23
billion and R$ 27 billion, respectively.
User industry: healthcare